TrueTicker

NIFTY 500 › Fast Moving Consumer Goods

Fast Moving Consumer Goods · NIFTY 500

Zydus Wellness Ltd.

ZYDUSWELL on NSE · 19 Nov 2026

NIFTY 500

455.85 ▼ -0.16 % on the day

Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance

Filings

35 filings of ZYDUSWELL since February 2025.

presentation 12, transcript 10, board outcome 7, results 2, dividend 2, bonus split 1

FiledTypeSubject
07 Nov 2026transcript
Guidance, Results
Zydus Wellness Limited has informed the Exchange about Transcript
AI summary

Zydus Wellness filed the transcript of its Q2 FY2027 earnings conference call held on November 3, 2026.

Management (CEO Tarun Arora) said consolidated net sales for Q2 FY27 were INR 11,227 million, up 74.6% year-on-year, and EBITDA was INR 855 million, up 271.7%.

For the half year ended September 30, 2026, net sales were INR 25,526 million (up 70.1%) and EBITDA was INR 3,272 million (up 83.2%).

Management said domestic portfolio grew 29.2% in Q2 and 13.3% in the half year, and international like-for-like growth was 12.4% in Q2 and 18.6% in the half year.

Management said Comfort Click growth slowed in the quarter due to timing shifts and a website transition in one market, and it remains committed to double-digit growth for that business.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Nov 2026presentation
Results
Zydus Wellness Limited has informed the Exchange about Investor Presentation
AI summary

Zydus Wellness filed its investor presentation on the unaudited financial results for the quarter and half year ended September 30, 2026 (Q2 FY2026-27), dated November 3, 2026.

The pages provided cover company overview, key milestones, global health and wellness trends, and consumption trend overview.

Management states that demand shows sustained positive momentum across categories, driven by steady urban recovery and improving rural offtake.

Management states that quick-commerce and e-commerce continue to gain share steadily.

The provided pages do not include the financial figures for the quarter.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Nov 2026board outcome
Results
Zydus Wellness Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
AI summary

Zydus Wellness Limited filed the outcome of its board meeting held November 3, 2026, approving unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026; Mukesh M. Shah & Co. issued limited review reports.

Standalone total income for Q2 FY27 was Rs 1,720 million (quarter ended September 30, 2026), against Rs 1,580 million in the year-ago quarter.

Standalone net profit for the quarter was Rs 116 million, against Rs 76 million a year earlier; for the half year it was Rs 171 million, against Rs 122 million.

Basic EPS for the quarter was Rs 0.36 (face value Rs 2 per share), against Rs 0.24 a year earlier.

The trading window remains closed until November 5, 2026 and reopens on November 6, 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
02 Sep 2026transcript
Acquisition, Management change, Results
Zydus Wellness Limited has informed the Exchange about Transcript of 32nd Annual General Meeting
AI summary

Zydus Wellness filed the transcript of its 32nd Annual General Meeting, held virtually on August 4, 2026 (10:00 to 10:48 A.M. IST).

Chairman Dr. Sharvil P. Patel said revenue from operations rose 46.2% to Rs. 36,610 million in FY26 and EBITDA grew 34.2% to Rs. 5,097 million, with seasonal brands hit by delayed summers and unseasonal rainfall.

Management said the acquisition of Comfort Click Limited (UK, with subsidiaries in Ireland, India and the US) strengthened its presence in vitamins, minerals and supplements, and that international business, including Comfort Click, delivered strong double-digit growth and is over 30% of revenue.

Board appointed Mr. Apurva Diwanji as additional Independent Director on May 18, 2026, subject to shareholder approval at the AGM.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
19 Aug 2026credit rating
Rating
Zydus Wellness Limited has informed the Exchange about Credit Rating
AI summary

Zydus Wellness Limited intimated that CARE Ratings Limited has assigned a credit rating to long-term bank facilities of Zydus Wellness Products Limited, a wholly owned material subsidiary.

Rated long-term bank facilities amount: ₹12.00 crore; rating: CARE AA+; Stable (assigned).

The intimation was received by email on August 18, 2026 at 6:43 p.m.

The rating is normally valid for one year from the initial communication date of July 22, 2026.

The credit rating letter and CARE press release were enclosed with the filing.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
10 Aug 2026transcript
Results
Zydus Wellness Limited has informed the Exchange about Transcript
AI summary

Zydus Wellness filed the transcript of its Q1 FY2027 earnings conference call held on August 4, 2026.

Management reported consolidated net sales of INR 14,299 million, up 66.7% year-on-year; EBITDA of INR 2,417 million, up 55.3%; and net profit down 7%, or up 26.5% excluding amortization of acquired brands.

Management said international business including Comfort Click grew 24.8% like-to-like, domestic business grew 4.6%, and seasonal brands declined 12% due to a softer summer season, particularly Nycil.

Management said the summer-season weakness was driven by rains in the East and North, and that Glucon-D and Nycil saw a recovery in the second half of the quarter.

Management said the effective tax rate for Q1 was close to 27% due to UK thin-cap disallowances, and that the effective finance cost was lower after a transition from a GBP loan to a EUR loan.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
04 Aug 2026presentation
Results
Zydus Wellness Limited has informed the Exchange about Investor Presentation
AI summary

Zydus Wellness Limited filed an investor presentation dated August 4, 2026, on its unaudited financial results for the quarter ended June 30, 2026 (Q1 FY 2026-27).

The pages provided cover company overview, key milestones since 1988, global health and wellness trends, and consumption trends (premiumization, quick-commerce and e-commerce growth).

The pages provided do not include the quarterly financial figures, so no revenue, profit or dividend numbers are stated here.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
04 Aug 2026board outcome
Results
Zydus Wellness Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
AI summary

Zydus Wellness Limited filed the outcome of its board meeting held August 4, 2026, approving unaudited standalone and consolidated results for the quarter ended June 30, 2026, reviewed by Mukesh M. Shah & Co.

Standalone total revenue from operations for Q1 FY27 was Rs 1,530 million, against Rs 1,326 million in the previous quarter and Rs 1,409 million a year earlier.

Standalone net profit for the quarter was Rs 55 million, against Rs 133 million in the previous quarter and Rs 46 million a year earlier.

Basic and diluted EPS (not annualised) were Rs 0.17 for the quarter, against Rs 0.42 in the previous quarter and Rs 0.14 a year earlier.

The trading window remains closed until August 6, 2026 and reopens on August 7, 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
22 May 2026transcript
Guidance, Results
Zydus Wellness Limited has informed the Exchange about Transcript
AI summary

Zydus Wellness filed the transcript of its Q4 FY2026 earnings conference call held on May 18, 2026.

Management said Q4 net sales grew 62.1% and FY26 net sales grew 46.4%, with international (including Comfort Click) like-to-like growth of 31.4% in Q4 and 29.5% for FY26, and domestic growth of 1.7% in Q4 and 2.4% for FY26.

Management reported Q4 EBITDA of INR 2,701 million (up 42.2%) and FY26 EBITDA of INR 5,097 million (up 34.2%); net profit fell 5.8% in Q4 and 43.2% for the year, and rose 17% (Q4) and 2.3% (FY) excluding exceptional items and amortization of acquired brands.

Management attributed the weak seasonal brands (down 9.8% in Q4 and 18.8% for FY26) to lower-than-normal temperatures and rains, and said it expects recovery from May onwards.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
18 May 2026presentationZydus Wellness Limited has informed the Exchange about Investor Presentation
AI summary

Zydus Wellness Limited filed its Investor Presentation on the audited financial results for the quarter and financial year ended March 31, 2026 (Q4 FY 2025-26 Earnings Presentation, dated May 18, 2026).

The pages provided cover the company overview, key milestones from 1988 to 2026, business infrastructure and distribution reach, but do not include the financial figures or management commentary.

Market capitalisation is stated as more than ₹160 bn as on April 30, 2026, with 1,500+ employees and 4 manufacturing facilities in India.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
18 May 2026dividend
Dividend / buy-back, Results
Zydus Wellness Limited has informed the Exchange that Board of Directors at its meeting held on May 18, 2026, recommended Final Dividend of Rs. 1.20 per equity share.
AI summary

Outcome of board meeting held May 18, 2026: audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 were approved and taken on record, with auditor Mukesh M. Shah & Co. reporting an unmodified opinion.

Board recommended a final dividend of ₹1.20 per equity share of ₹2 each (60%), subject to shareholder approval at the AGM scheduled for August 4, 2026.

The trading window remains closed until May 20, 2026 and reopens on May 21, 2026 for directors and designated persons.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
18 May 2026board outcome
Dividend / buy-back, Results
Zydus Wellness Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
AI summary

Zydus Wellness Limited filed the outcome of its board meeting held on May 18, 2026, approving the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026.

The statutory auditor, Mukesh M. Shah & Co., issued audit reports with an unmodified opinion on both standalone and consolidated results.

The board recommended a final dividend of ₹1.20 per equity share of ₹2 each (60%), subject to shareholder approval at the AGM scheduled for August 4, 2026.

The trading window remains closed until May 20, 2026 and reopens on May 21, 2026 for directors and designated persons.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
18 Mar 2026presentationZydus Wellness Limited has informed the Exchange about Investor Presentation
AI summary

Zydus Wellness filed a revised investor presentation, to be made at analyst and institutional investor conferences on March 18 and 19, 2026, following an earlier intimation dated March 16, 2026.

The presentation covers the company's key milestones from 1988 to 2026, including acquisitions of Heinz India, Carnation Nutra, Naturell (India) and Comfort Click, and a capital restructuring of Rs. 10,000 million (QIP and preferential issue) plus repurchase of NCDs of Rs. 15,000 million.

It also describes the board of directors, business overview (1,600+ employees, Rs. 126+ bn market cap, 4 manufacturing facilities in India, 80,000+ shareholders) and distribution reach (1,950+ distributors, ~2.8 million stores).

The presentation includes a forward-looking statements safe harbour disclaimer.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
16 Mar 2026presentationZydus Wellness Limited has informed the Exchange about Investor Presentation
AI summary

Zydus Wellness Limited filed an investor presentation dated March 2026, to be made at analyst/institutional investor conferences on March 18 and 19, 2026, under Regulation 30 of the Listing Regulations.

The presentation is also uploaded on the company website at www.zyduswellness.com.

The pages provided cover company milestones, the board of directors, and business overview points: 1,600+ employees, ₹126+ bn market cap, 80,000+ shareholders, 4 manufacturing facilities in India, and reach to over 70 million families.

The pages provided contain no financial results, guidance or dividend figures.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
09 Feb 2026transcript
Acquisition, Guidance, Results
Zydus Wellness Limited has informed the Exchange about Transcript
AI summary

Zydus Wellness filed the transcript of its Q3 FY2026 earnings conference call held on February 3, 2026.

Management said consolidated net sales grew 113.7% year-on-year in Q3 FY26, with Food & Nutrition up 134% and Personal Care down 1.4%; consolidated EBITDA was INR610 million, with EBITDA margin of 6.3% versus 3.2% a year earlier.

Management said the net loss including exceptional items and non-cash amortization was INR399 million, and the adjusted net loss excluding exceptional items was INR333 million.

Management expects Comfort Click gross margin on an annualised basis of about 66-67% on a consolidated basis, and aims for Comfort Click EBITDA margins above 14% and base business margins of 16-18% over the next one to two years.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Feb 2026presentation
Results
Zydus Wellness Limited has informed the Exchange about Investor Presentation
AI summary

Zydus Wellness Limited filed an investor presentation dated February 3, 2026 on its unaudited financial results for the quarter and nine months ended December 31, 2025 (Q3 FY 2025-26).

The first pages show the presentation's contents: company overview and consumption trend, product portfolio (brands include Glucon D, Rite Bite Max, Protein, Nutralite, Complan, Sugarfree, I'm Lite, WeightWorld, maxmedix, animigo, Everyuth, Nycil and Cuticolor), business highlights, financial performance and board of directors.

The extracted pages do not include the financial figures or any management commentary.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Feb 2026board outcome
Results
Zydus Wellness Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
AI summary

Zydus Wellness Limited filed the outcome of its board meeting held February 3, 2026, approving unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025.

Standalone total income for the quarter ended December 31, 2025 was Rs 1,570 million; net profit was Rs 121 million, against Rs 118 million a year earlier.

Standalone revenue from operations for the nine months ended December 31, 2025 was Rs 4,495 million, against Rs 2,264 million a year earlier; net profit was Rs 243 million, against Rs 260 million.

Exceptional items for the quarter included Rs 97 million for expenses related to the liquidation of Naturell (India) Private Limited and Rs 15 million as a one-time impact of the New Labour Codes.

The trading window remains closed until February 5, 2026 and reopens on February 6, 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
10 Nov 2025transcript
Acquisition, Legal, Results
Zydus Wellness Limited has informed the Exchange about Transcript
AI summary

Zydus Wellness filed the transcript of its Q2 FY2026 earnings conference call held on November 5, 2025.

Management said consolidated net sales grew 31% for the quarter and 12.8% for H1 FY26, driven by newly acquired entities, offsetting seasonal product pressure; consolidated EBITDA was INR230 million, up 17.3% year-on-year.

Management reported a net loss of INR528 million including exceptional items, and an adjusted net loss of INR186 million excluding exceptional items.

Management said the Comfort Click acquisition (UK, EU and US presence) was funded by a bridge loan at 5% on about GBP240 million, with brand amortization of about INR2,400 crore over 15 years (about INR40 crore per quarter).

Management said the Comfort Click business had been consolidated for about one month and that the bridge loan may be replaced by equity or borrowing in a couple of quarters.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 Nov 2025presentation
Results
Zydus Wellness Limited has informed the Exchange about Investor Presentation
AI summary

Zydus Wellness filed its investor presentation on the unaudited financial results for the quarter and half year ended September 30, 2025 (Q2 FY2025-26 earnings presentation), dated November 5, 2025.

The pages provided include the cover letter, safe harbour statement, company overview and product portfolio slides (Glucon D, Rite Bite, Max Protein, Nutralite, Complan, Sugarfree, I'm Lite, WeightWorld, maxmedix, animigo, Nycil, Everyuth).

The provided pages do not include the financial figures, revenue, profit or management commentary.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 Nov 2025board outcome
Results
Zydus Wellness Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
AI summary

Zydus Wellness Limited filed the outcome of its board meeting held November 5, 2025, approving unaudited standalone and consolidated results for the quarter and half year ended September 30, 2025, with a limited review report from Mukesh M. Shah & Co.

Standalone total income for Q2 FY26 (quarter ended September 30, 2025) was Rs 1,580 million versus Rs 674 million a year earlier; net profit was Rs 76 million versus Rs 80 million.

Standalone net profit for the half year ended September 30, 2025 was Rs 122 million versus Rs 142 million in the corresponding period last year; basic EPS for the half year was Rs 0.38.

The results include an exceptional item of Rs 97 million related to the liquidation of Naturell (India) Private Limited, which was consolidated into the company with effect from September 20, 2025.

The trading window remains closed until November 7, 2025 and reopens on November 10, 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
29 Aug 2025presentation
Acquisition
Zydus Wellness Limited has informed the Exchange about Investor Presentation
AI summary

Zydus Wellness Limited filed a presentation and disclosure under Regulation 30 on the acquisition of Comfort Click Limited, UK, by its wholly owned subsidiary Alidac UK Limited.

Alidac acquired 100% of Class A and Class B ordinary shares, 71.43% of non-controlling Class C shares and 66.67% of non-controlling Class D shares of Comfort Click, for cash consideration of GBP 239 million plus agreed profit from the lock box date (March 31, 2025) to closing, subject to adjustments.

The transaction was signed and concluded on August 29, 2025; Comfort Click becomes a wholly owned subsidiary of Alidac and a step-down subsidiary of the company.

Comfort Click reported unaudited revenue from operations of GBP 134 million for the year ended June 30, 2025, against GBP 85 million for FY2024 and GBP 52 million for FY2023.

Comfort Click operates in the vitamins, minerals and supplements segment in the UK and Europe, and is expanding in the USA; management called it the company's first overseas acquisition.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 Aug 2025transcript
Acquisition, Capex, Results
Zydus Wellness Limited has informed the Exchange about Transcript of 31st AGM
AI summary

Transcript of the 31st Annual General Meeting of Zydus Wellness Limited, held by video conferencing on July 30, 2025 (10:00 to 10:42 A.M. IST).

Chairman Dr. Sharvil P. Patel said FY25 revenue from operations grew 16.4% to ₹27,089 million, EBITDA rose 23.2% to ₹3,797 million and net profit rose 30% to ₹3,469 million.

Management said capital expenditure of ₹663 million was made for innovation, infrastructure and automation, and operating cash flow was ₹3,800 million.

Management said Personal Care grew 33.4% and Food and Nutrition grew 13.0% in FY25, and that the Naturell (India) Private Limited acquisition (RiteBite brands) was completed.

Members holding 69.6% of share capital had submitted representations under section 113; the meeting was on the Notice of AGM dated May 19, 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 Aug 2025transcript
Guidance, Results
Zydus Wellness Limited has informed the Exchange about Transcript
AI summary

Zydus Wellness filed the transcript of its Q1 FY2026 earnings conference call held on July 30, 2025.

Management said consolidated net sales grew 2.2% to Rs. 8,577 million; excluding seasonal brands, growth was double-digit, and organic volume and value growth was near flattish including seasonal brands.

Management said gross margin declined 73 basis points at the overall level, EBITDA grew 0.2% to Rs. 1,556 million, and PAT declined 13.4%, mainly due to non-cash amortization and deferred tax items.

Management said it expects a structural double-digit revenue growth path over the next 2 to 3 years and remains on track for its two-year EBITDA margin expansion journey, with direct outlets targeted to rise to about 7 lakh by end of FY2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jul 2025presentationZydus Wellness Limited has informed the Exchange about Investor Presentation
AI summary

Zydus Wellness filed its Q1 FY 2025-26 investor presentation dated July 30, 2025, on the unaudited financial results for the quarter ended June 30, 2025.

The pages provided cover the company overview, product portfolio (Glucon D, Complan, Sugarfree, I'm Lite, Nycil, Everyuth and others) and a global health and wellness trends slide.

The pages provided do not include the financial figures, so revenue and profit numbers cannot be stated from this excerpt.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jul 2025board outcome
Acquisition, Results
Zydus Wellness Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
AI summary

Board of Zydus Wellness Limited approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 at its meeting held on July 30, 2025; limited review reports from Mukesh M. Shah & Co. are enclosed.

Standalone revenue from operations for Q1 FY26 was Rs 877 million, against Rs 634 million in the quarter ended June 30, 2024.

Standalone net profit was Rs 70 million, against Rs 62 million a year earlier; basic EPS was Rs 1.10 (not annualised).

Note 5: on July 1, 2025 shareholders of Naturell (India) Private Limited approved its voluntary liquidation on a going concern basis, with its business undertaking to be distributed to the Company as sole shareholder.

Trading window remains closed until August 1, 2025 and reopens on August 4, 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
23 May 2025transcript
Acquisition, Dividend / buy-back, Guidance, Results
Zydus Wellness Limited has informed the Exchange about Transcript
AI summary

Zydus Wellness filed the transcript of its Q4 FY2025 earnings conference call held on May 19, 2025, under Regulations 30 and 46(2)(oa)(iii) of the SEBI Listing Regulations.

Management said Q4 consolidated net sales grew 17% to INR 9,106 million, with volume growth of 13%; FY2025 net sales grew 16.2% to INR 26,912 million.

Management reported Q4 EBITDA up 17.1% to INR 1,900 million and net profit after tax up 14.4% to INR 1,719 million; FY2025 EBITDA rose 23.2% to INR 3,797 million.

The Board recommended a final dividend of INR 6 per equity share (face value INR 10) and a stock split of 1:5 reducing face value to INR 2, both subject to shareholder approval at the AGM.

Management said its intent is to move EBITDA margin to 17-18% in the next couple of years, and that the Rite Bite business (Naturell India, acquired 100%) grew over 50% in about four months with low single-digit positive margins.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
19 May 2025presentationZydus Wellness Limited has informed the Exchange about Investor Presentation
AI summary

Zydus Wellness filed its investor presentation on the audited financial results for the quarter and year ended March 31, 2025 (Q4 FY 2024-25 Earnings Presentation, dated May 19, 2025).

The excerpt provided covers only the cover letter, safe harbour statement, new brand identity, agenda and business overview pages.

The business overview states over 70 million families served, 4 manufacturing facilities in India, over 1,000 employees, market cap above ₹100 billion and about 65,000 shareholders.

The financial figures, results numbers and management commentary are not included in the pages provided.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
19 May 2025bonus split
Dividend / buy-back, Legal, Results
Zydus Wellness Limited has informed the Exchange that the Board of Directors at its meeting held on May 19, 2025, has considered and approved subdivision of 1 equity shares of Rs. 10 each into 5 equity shares of Rs. 2 each.
AI summary

Board of Zydus Wellness Limited recommended a final dividend of ₹6.00 per equity share (60% on ₹10 face value), subject to members' approval at the AGM on July 30, 2025; record date is Friday, July 11, 2025, and payment on or after August 4, 2025.

Board proposed sub-division of equity shares: 1 equity share of ₹10 face value split into 5 equity shares of ₹2 each, subject to members' approval at the AGM; post-split issued and paid-up capital remains ₹63,63,21,440 (31,81,60,720 shares of ₹2 each after split, versus 6,36,32,144 shares of ₹10 before).

Board approved appointment of Hitesh Buch & Associates as Secretarial Auditors for five years from FY 2025-26 to FY 2029-30, subject to members' approval.

Board approved re-appointment of Mukesh M. Shah & Company, Chartered Accountants, as Statutory Auditors for a second five-year term, from conclusion of the 31st AGM to conclusion of the 36th AGM, subject to members' approval.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
19 May 2025dividend
Dividend / buy-back, Results
Zydus Wellness Limited has informed the Exchange that Board of Directors at its meeting held on May 19, 2025, recommended Final Dividend of Rs. 6.00 per equity share.
AI summary

Zydus Wellness Limited filed the outcome of its board meeting held on May 19, 2025, approving the audited standalone and consolidated financial results for the quarter and year ended March 31, 2025.

The statutory auditors, Mukesh M. Shah & Co., issued unmodified audit opinions on both the standalone and consolidated results.

The board recommended a final dividend of ₹6.00 per equity share of ₹10 each (60%), subject to shareholder approval at the AGM scheduled for July 30, 2025.

The trading window remains closed until May 21, 2025, and reopens for directors and designated persons on May 22, 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
19 May 2025board outcome
Dividend / buy-back, Results
Zydus Wellness Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
AI summary

Zydus Wellness Limited filed the outcome of its board meeting held on May 19, 2025, approving the audited standalone and consolidated financial results for the quarter and year ended March 31, 2025.

The statutory auditors, Mukesh M. Shah & Co., issued unmodified audit opinions on both standalone and consolidated results.

The board recommended a final dividend of ₹6.00 per equity share (60%) of face value ₹10 each, subject to shareholder approval at the AGM scheduled for July 30, 2025.

The trading window remains closed until May 21, 2025, and reopens on May 22, 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
10 Feb 2025transcript
Acquisition, Guidance, Results
Zydus Wellness Limited has informed the Exchange about Transcript
AI summary

Zydus Wellness filed the transcript of its Q3 FY2025 earnings conference call held on February 4, 2025, under Regulations 30 and 46(2)(oa)(iii) of the SEBI LODR Regulations.

Management said consolidated net sales grew 12.7% to INR 4,508 million, with volume growth of 4.8% year-on-year, and EBITDA grew 16.5% year-on-year to INR 148 million; net profit after tax was INR 64 million.

Management said Personal Care segment sales grew 50.3% in the quarter and Food & Nutrition grew 8.8%, and that the Naturell (India) Private Limited acquisition was completed in the later part of the quarter, contributing a low single-digit share of top line at breakeven EBITDA.

Management guided to double-digit top-line growth in FY26 with EBITDA growth in line with or faster than top-line growth, and said EBITDA margins could reach a much higher level over the next 6 to 8 quarters.

Management said urban demand remains sluggish, that the demand setback is expected to be temporary, and that it expects a revival in coming quarters.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
04 Feb 2025results
Results
Integrated Filing (Financials) for the quarter and nine months ended December 31, 2024
AI summary

Zydus Wellness Limited filed its integrated filing with standalone unaudited financial results for the quarter and nine months ended December 31, 2024, approved by the Board on February 4, 2025.

Q3 FY25 (quarter ended Dec 31, 2024) standalone total income was Rs 915 million and net profit was Rs 117 million, against Rs 80 million in the preceding quarter (Sept 30, 2024) and Rs 103 million in the year-ago quarter.

Nine-month standalone total income was Rs 2,271 million and net profit was Rs 259 million, compared with Rs 1,950 million and Rs 263 million in the nine months ended Dec 31, 2023.

Basic and diluted EPS for the quarter was Rs 1.84 (not annualised), against Rs 1.62 a year earlier; the statutory auditors carried out a limited review.

The filing states there is no default on outstanding loans and the company has not issued any debt securities.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
04 Feb 2025presentation
Results
Zydus Wellness Limited has informed the Exchange about Investor Presentation
AI summary

Zydus Wellness filed its Q3 FY2024-25 investor presentation on the unaudited financial results for the quarter and nine months ended December 31, 2024.

Q3 FY25 net sales were INR 4,508 million, up 12.7% year-on-year from INR 4,001 million in Q3 FY24.

Food & Nutrition segment Q3 FY25 net sales grew 50.3% year-on-year... [see note]

Personal Care segment Q3 FY25 net sales grew 8.8% year-on-year.

YTD December FY25 net sales were INR 17,806 million, up 15.8% from INR 15,372 million in the prior-year period.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
04 Feb 2025presentation
Results
Zydus Wellness Limited has informed the Exchange about Investor Presentation
AI summary

Zydus Wellness filed its Q3 FY2024-25 investor presentation on the unaudited financial results for the quarter and nine months ended December 31, 2024.

Q3 FY25 net sales were INR 4,508 million, up 12.7% year-on-year from INR 4,001 million in Q3 FY24.

Food & Nutrition segment Q3 FY25 growth was 50.3% year-on-year and Personal Care segment growth was 8.8% year-on-year (as labelled in the slides).

YTD December FY25 net sales were INR 17,806 million, up 15.8% year-on-year from INR 15,372 million; the slides label segment growth of 39.2% and 11.8% for the YTD period, but the segment attribution of these figures is not clear from the text.

The presentation notes that consumption trends remain subdued for the industry, with rural consumption steady, smaller unit packs growing faster and inflationary pressure affecting consumption and input prices.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
04 Feb 2025results
Results
Zydus Wellness Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
AI summary

Zydus Wellness Limited's board approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024 on February 4, 2025, with Limited Review Reports from Mukesh M. Shah & Co.

Standalone total revenue from operations for the quarter ended December 31, 2024 was Rs 884 million, against Rs 638 million in the quarter ended December 31, 2023; net profit was Rs 117 million, against Rs 103 million.

Standalone total revenue from operations for the nine months ended December 31, 2024 was Rs 2,151 million, against Rs 1,817 million a year earlier; net profit was Rs 259 million, against Rs 263 million.

Basic EPS (not annualised) for the quarter was Rs 1.84, and for the nine months Rs 4.07.

The trading window remains closed until February 6, 2025 and reopens on February 7, 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy

The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in